

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)



(10) International Publication Number
WO 2022/058945 A1

(51) International Patent Classification:

A61K 39/108 (2006.01) A61P 31/04 (2006.01)
A61P 13/00 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2021/058485

(22) International Filing Date:

17 September 2021 (17.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/079,734 17 September 2020 (17.09.2020) US
21154782.3 02 February 2021 (02.02.2021) EP
63/191,471 21 May 2021 (21.05.2021) US

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicant: JANSSEN PHARMACEUTICALS, INC.
[US/US]; 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (US).

(72) Inventors: POOLMAN, Jan, Theunis; c/o Janssen Vaccines & Prevention B.V., Archimedesweg 4-6, 2333 CN Leiden (NL). FAE, Kellen, Cristhina; c/o Janssen Vaccines & Prevention B.V., Archimedesweg 4-6, 2333 CN Leiden (NL). SARNECKI, Michal; c/o Janssen Vaccines, Branch of Cilag GmbH International, Reihagstrasse 79, 3018 Bern (CH). GEURTSSEN, Jeroen; c/o Janssen Vaccines & Prevention B.V., 2333 CN Leiden (NL). AB-BANAT, Darren, Robert; c/o Janssen Vaccines & Prevention B.V., 2333 CN Leiden (NL). SPIESSENS, Bart, Gustaaf, M.; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). STRUYF, Frank, Germaine, F.; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOF

(57) Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic *Escherichia coli* (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of *E. coli* polysaccharide antigen O75 covalently bound to a carrier protein for the prevention of invasive ExPEC disease.



WO 2022/058945 A1